Resources

All Resources

Our resource hub to discover reports, policy papers and other forms of informative content

Filter by

PMPRB Notice and Comment Response

Innovative Medicines Canada opposes a July 15, 2021 proposal to change international price tests for existing medicines and their line extensions from the highest of the international schedule to the median.

Learn more|View

Letter to the Honourable Patty Hajdu

IMC requests that the Honourable Patty Hadju suspend the July 1, 2021 implementation of regulatory changes to the PMPRB until the COVID-19 pandemic has abated.

Learn more|View

2021 Federal Pre-Budget Consultation

The industry calls on the federal government to delay implementation of PMPRB regulatory changes until the COVID-19 pandemic has abated. IMC urges the federal government to work with our industry to build a more vibrant life sciences sector – one that enhances patients’ access to innovative medicines and tackles the sector’s critical issues.

Learn more|View

PMPRB Guidelines Notice and Comment

IMC opposes a January 15, 2021 proposal to redefine ‘gap’ medicines and change the timeline for compliance – which halves the transition period to six months.

Learn more|View

House of Commons Standing Committee on Health (HESA)

The industry campaigns to remove experimental “new economic factors” from regulations – the source of most stakeholder concerns amid 2020 PMPRB changes. IMC encourages government to delay implementation of changes until the COVID-19 pandemic has abated.

Learn more|View

IMC Response to PMPRB Draft Guidelines

IMC responds to PMPRB draft guidelines released November 21, 2019, stating a balance must be struck between budgetary pressures confronting Canadian governments and the preservation of Canadians’ timely access to life-saving innovative medicines.

Learn more|View

resources

Discover. Learn.
Understand.

Informative content to keep you up to date on the most pressing issues facing our industry.